The food and drug administration and the future of drug development for the treatment of diabetes

Diabetes Spectrum

Volumn 27, Issue 2, 2014, Pages 75-77

  Brass, Eric P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; GLUCOSE; INSULIN DEGLUDEC; ROFECOXIB; ROSIGLITAZONE; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; TROGLITAZONE;

CARDIOVASCULAR RISK; DECISION MAKING; DIABETES MELLITUS; DRUG APPROVAL; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE PERSONNEL; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; STUDY DESIGN;

EID: 84901935974     PISSN: 10409165     EISSN: 19447353     Source Type: Journal    
DOI: 10.2337/diaspect.27.2.75     Document Type: Editorial

References (15)

1. From the Food and Drug Administration. JAMA 283:2228, 2000
2. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007 (Pubitemid 46919772)
3. Brass EP, Lewis RJ, Lipicky R, Murphy J, Hiatt WR: Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther 79:165-172, 2006
4. Fleming TR: Current issues in non-inferiority trials. Stat Med 27:317-332, 2008
5. Fleming TR: Identifying and addressing safety signals in clinical trials. N Engl J Med 359:1400-1402, 2008
6. Lazarus D: Avandia: when does a drug's harm outweigh its benefits? Los Angeles Times 1 July 2010. Available from http://articles.latimes.com/2010/jul/ 01/business/la-fi-lazarus-20100702. Accessed 25 November 2013
7. U.S. Food and Drug Administration: Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 2 October 2009
8. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell, JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317-1326, 2013
9. Tucker ME: FDA rejects Novo Nordisk's insulin degludec. Medscape 11 February 2013. Available from http://www.medscape.com/viewarticle/779077. Accessed 25 November 2013
10. U.S. Food and Drug Administration: Joint Meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees, 5 June 2013 [Transcript]. Available from http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM369182.pdf. Accessed 25 November 2013
11. U.S. Food and Drug Administration: Joint Meeting of the Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory Committees, 6 June 2013 [Transcript]. Available from http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM369183.pdf. Accessed 25 November 2013
12. Feeley J, Kelley T: Glaxo said to pay $460 million to settle Avandia damage suits. Available from http://www.bloomberg.com/news/2010-07-13/ glaxosmithkline-is-said-to-pay-460-million-to-settle-avandia-damage-suits.html. Accessed 25 November 2013
13. Brass EP: Assessing the benefit-risk for new drugs: are the FDA's Endocrinologic and Metabolic Drugs Advisory Committee and the Division of Metabolism and Endocrinology Products in sync? Diabetes Care 36:1823-1826, 2013
14. Brass EP, Hiatt WR: Improving the FDA's advisory committee process. J Clin Pharmacol 52:1277-1283, 2012
15. U.S. Food and Drug Administration: Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee, 28-29 March 2012 [Minutes]. Available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303352.pdf. Accessed 25 November 2013